At Skin Analytics research is at the very core of everything that we do.
Ever since we were founded we’ve been working with top tier machine learning research groups from the Universities of Oxford, Cambridge and Bristol and Imperial College London.
We’ve also worked with internationally recognised clinicians involved at all stages of the skin cancer pathway, as well as experts in health economics. We have formalised these relationships into our Clinical Advisory Committee, which guides our research and services.
We’ve undertaken a study on over 6,000 biopsy confirmed mole images.
The results of this study confirmed that our AI, Deep Ensemble for the Recognition of Malignancy (DERM), is as accurate as a dermatologist. We have the results and are publishing the paper soon. Watch this space.
We’ve conducted the world’s first prospective study for AI and melanoma.
We’re just finished the world’s first clinical trial for AI melanoma detection across 7 NHS hospitals, led by the Royal Free London.
The study was designed by leading clinicians to ensure that results truly represent the efficacy of our solution compared to clinicians in a realistic setting. We will be publishing the paper on this study shortly.
We partnered with Advance Queensland under an Ignite Grant and are conducting a study into the health economic benefits of using DERM to help detect skin cancer in primary care.
With the help of leading researchers at Griffith University we have designed a study to work alongside GP’s to help establish how the use of DERM would affect the rate of biopsies conducted. We plan to show that the use of AI in primary care can reduce the number of biopsies needed to find skin cancer.
We would like to thank Ignite Queensland, Griffith University and Pioneer Health for their support with our research.